LEAP2 and metabolic syndrome: Fasting plasma/serum LEAP2 did not fall significantly after RYGB surgery in obesity with metabolic dysfunction–associated fatty liver disease (MAFLD) at 6 months with an approximately 29% weight loss despite marked improvements in insulin resistance and fasting plasma glucose [65], nor after VSG surgery in obesity with T2DM at 12 months with an approximately 28% weight loss despite marked improvements in glycemic control and markers of metabolic syndrome [66].